Raltegravir · Isentress

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HIV

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Isentress Tablets 400 mg (raltegravir potassium), anti-HIV agent; applicant Banyu Pharmaceutical (Merck subsidiary, now MSD K.K.); approved as a new drug with orphan designation
Product first approved 2008pj.jiho.jp
EU
  • Isentress: HIV-1 infection, in combination with other antiretroviral medicinal products (conditional authorisation, full authorisation 2009-07-14)
Product first approved 2007EMA
CA
  • ISENTRESS® (raltegravir) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg. ISENTRESS HD® (raltegravir) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients weighing at least 40 kg.
Product first approved 2007Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
HIV
NCT03029689 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2017-07-28 – 2020-04-30 · HIV
What this study did
NCT01900106 · University of Modena and Reggio Emilia
2013-11 – 2017-12 · HIV Infection
What this study did
NCT02284035 · Juan A. Arnaiz
2015-09-27 – 2017-02-28 · AIDS
What this study did
NCT01825031 · Anna Griffiths, MRC
2013-06 – 2016-03 · Human Immunodeficiency Virus
What this study did
NCT01453192 · ANRS, Emerging Infectious Diseases
2011-12 – 2015-11 · HIV-1 Infection, Chronic Renal Insufficiency
What this study did
NCT02247687 · ANRS, Emerging Infectious Diseases
2014-12 – 2015-09 · HIV-1 Infection, Treatment Resistant Disorders, Viremia
What this study did
NCT01352715 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2012-03-13 – 2014-10-29 · HIV-1 Infection
What this study did
NCT00935480 · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
2010-10 – 2014-08-08 · HIV Infections
What this study did
NCT00887653 · The Miriam Hospital
2009-05 – 2014-04 · HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
What this study did
NCT01697046 · Projeto Praça Onze
2012-11 – 2014-03 · Infection, HIV
What this study did
NCT00988039 · Justine Boles
2010-03 – 2014-01 · Human Immunodeficiency Virus, HIV
What this study did
NCT00984152 · Rush University Medical Center
2011-06 – 2013-12 · HIV-1 Infections
What this study did
NCT01066962 · ANRS, Emerging Infectious Diseases
2010-08 – 2013-10 · HIV Infections
What this study did
NCT00811954 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2009-05 – 2013-06 · HIV Infection
What this study did
NCT01195467 · St Stephens Aids Trust
2010-10 – 2013-06 · HIV Infection
What this study did
NCT00537394 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-01 – 2013-04 · HIV Infections
What this study did
NCT01114425 · Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
2010-11-01 – 2012-12-01 · HIV Infections
What this study did
NCT00785967 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2009-01 – 2011-08 · HIV Infections
What this study did
NCT00874523 · Kirby Institute
2009-07 – 2011-07 · HIV Infection
What this study did
NCT00745823 · Merck Sharp & Dohme LLC
2008-09 – 2011-05 · HIV
What this study did
NCT00764946 · Merck Sharp & Dohme LLC
2008-10 – 2011-02 · Human Immunodeficiency Virus
What this study did
NCT00562510 · Pedro Cahn
2008-08 – 2010-12 · HIV Infections
What this study did
NCT00528892 · Hospital Clinic of Barcelona
2008-01 – 2010-03 · HIV Infections
What this study did
NCT00529243 · Kaiser Permanente
2007-09 – 2009-09 · HIV Infections
What this study did
NCT00554398 · Germans Trias i Pujol Hospital
2007-11 – 2009-09 · HIV Infections
What this study did
NCT00443703 · Merck Sharp & Dohme LLC
2007-05 – 2009-04 · HIV Infection
What this study did
NCT00443729 · Merck Sharp & Dohme LLC
2007-05 – 2009-04 · HIV Infection
What this study did
NCT00454337 · French National Agency for Research on AIDS and Viral Hepatitis
2007-05 – 2008-09 · HIV Infections
What this study did
Phase 2/3 (3)
HIV
NCT01854762 · Fundação Bahiana de Infectologia
2015-06-01 – 2017-08-02 · HIV, Pregnancy
What this study did
NCT01154673 · University of Toronto
2011-11 – 2014-09 · Acute HIV Infection
What this study did
NCT00729924 · Vanderbilt University
2008-08 – 2011-08 · HIV Infections
What this study did
Phase 2 (35)
HIV
NCT04513626 · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
2020-09-15 – 2025-10-30 · HIV Infections
What this study did
NCT02336074 · Imperial College London
2015-11-27 – 2023-03-31 · HIV
What this study did
NCT03195452 · Nantes University Hospital
2017-11-08 – 2020-05-06 · Virus-HIV
What this study did
NCT02212379 · ANRS, Emerging Infectious Diseases
2015-01 – 2018-04 · HIV-1 Infection
What this study did
NCT01601626 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2013-07-13 – 2017-06-28 · HIV Infection, Tuberculosis
What this study did
NCT01384734 · ViiV Healthcare
2011-07-26 – 2017-05-12 · Infection, Human Immunodeficiency Virus
What this study did
NCT02025868 · ANRS, Emerging Infectious Diseases
2013-03 – 2017-05 · HIV Infection
What this study did
NCT02099474 · ANRS, Emerging Infectious Diseases
2014-06-30 – 2017-04 · HIV-1 Infection, PREGNANCY
What this study did
NCT01231685 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2011-12 – 2016-09 · HIV, Hepatitis C, Liver Fibrosis
What this study did
NCT01291459 · Association Pour la Recherche en Infectiologie
2011-09 – 2015-12 · HIV
What this study did
NCT02097108 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2014-05 – 2015-12 · HIV Infections
What this study did
NCT01605890 · ANRS, Emerging Infectious Diseases
2012-07 – 2015-12 · HIV-2 Infection
What this study did
NCT00976404 · Robert L. Murphy
2009-11 – 2014-06 · HIV Infection
What this study did
NCT00752856 · University of California, San Diego
2008-08-26 – 2014-02-11 · HIV Infections
What this study did
NCT01420523 · ANRS, Emerging Infectious Diseases
2011-12 – 2013-04 · Human Immunodeficiency Virus, Lipohypertrophy
What this study did
NCT00822315 · ANRS, Emerging Infectious Diseases
2009-07 – 2012-05 · HIV Infections, Tuberculosis
What this study did
NCT00654147 · Margaret A. Fischl, M.D.
2008-04 – 2012-01 · HIV Infections
What this study did
NCT00656175 · University of California, Los Angeles
2008-09 – 2011-12 · HIV Infections, Lipodystrophy
What this study did
NCT00807443 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2009-09 – 2011-12 · HIV-1, HIV Infections
What this study did
NCT00520897 · Canadian Immunodeficiency Research Collaborative
2007-04 – 2011-11 · HIV Infections
What this study did
NCT00943540 · Radboud University Medical Center
2009-07 – 2011-01 · HIV Infection, HIV Infections
What this study did
NCT00958100 · Catholic University of the Sacred Heart
2009-08 – 2010-12 · HIV/AIDS, Antiretroviral Therapy, HIV Infections
What this study did
NCT01159132 · The HIV Netherlands Australia Thailand Research Collaboration
2010-04 – 2010-12 · HIV Infections
What this study did
NCT00830804 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2009-04 – 2010-09 · HIV-1 Infections
What this study did
NCT00100048 · Merck Sharp & Dohme LLC
2005-01 – 2010-07 · HIV Infections, Acquired Immunodeficiency Syndrome
What this study did
NCT00768989 · Bristol-Myers Squibb
2008-11 – 2010-05 · HIV
What this study did
NCT00460382 · French National Agency for Research on AIDS and Viral Hepatitis
2007-05 – 2009-09 · HIV Infections
What this study did
NCT00105157 · Merck Sharp & Dohme LLC
2005-03 – 2009-07 · HIV Infections, Acquired Immunodeficiency Syndrome
What this study did
NCT00515827 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-11 – 2008-11 · HIV Infections
What this study did
NCT00614458 · University of North Carolina, Chapel Hill
2007-04 – 2008-09 · HIV Infections
What this study did
Other / comorbidity
NCT03954327 · University of Alberta
2021-03-01 – 2024-01-01 · Primary Biliary Cholangitis
What this study did
NCT01620736 · Washington University School of Medicine
2012-01 – 2014-12 · Human T-cell Leukemia Virus Type 1 Infection
What this study did
NCT01767701 · Queen Mary University of London
2013-04 – 2014-09 · Relapsing Remitting Multiple Sclerosis
What this study did
Phase 1/2 (6)
HIV
NCT02140255 · National Institute of Allergy and Infectious Diseases (NIAID)
2015-01-23 – 2031-12-31 · HIV Infection
What this study did
NCT01751568 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-11-12 – 2019-11-27 · HIV Infections, Tuberculosis
What this study did
NCT00485264 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-09-17 – 2017-05-18 · HIV Infections
What this study did
NCT01022476 · ANRS, Emerging Infectious Diseases
2010-05 – 2013-05 · HIV Infection, Liver Failure, Evidence of Liver Transplantation
What this study did
Other / comorbidity
NCT01000285 · Washington University School of Medicine
2010-09 – 2016-04 · Leukemia-Lymphoma, Adult T-Cell
What this study did
Phase 1 (44)
HIV
NCT03174977 · University of California, San Francisco
2018-04-01 – 2025-01-01 · HIV-1-infection
What this study did
NCT01780831 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-01-28 – 2018-04-20 · HIV Infections
What this study did
NCT01784302 · Helen Reynolds
2014-04 – 2016-02 · HIV
What this study did
NCT02473367 · Merck Sharp & Dohme LLC
2015-06-23 – 2015-10-09 · HIV Infection
What this study did
NCT02489487 · Viriom
2014-09 – 2014-10 · HIV-infection
What this study did
NCT01978782 · Radboud University Medical Center
2014-01 – 2014-04 · HIV, Depression
What this study did
NCT01930045 · Merck Sharp & Dohme LLC
2013-10-01 – 2013-12-10 · HIV Infections
What this study did
NCT01841593 · St Stephens Aids Trust
2013-04 – 2013-09 · HIV
What this study did
NCT01779687 · Radboud University Medical Center
2013-03 – 2013-08 · HIV, Hypercholesterolaemia
What this study did
NCT01424826 · Helen Reynolds
2012-01 – 2013-07 · HIV, Tuberculosis
What this study did
NCT01622673 · Merck Sharp & Dohme LLC
2012-06 – 2012-10 · HIV Infections
What this study did
NCT00667433 · David A Wohl, MD
2008-06 – 2011-12 · HIV Infections
What this study did
NCT01288417 · Radboud University Medical Center
2011-08 – 2011-12 · HIV Infections, HCV Infections
What this study did
NCT01289951 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2010-12 – 2011-10 · Human Immunodeficiency Virus, Hepatitis C
What this study did
NCT01288755 · Tibotec Pharmaceuticals, Ireland
2011-02 – 2011-05 · HIV Infections
What this study did
NCT01246804 · Radboud University Medical Center
2010-11 – 2011-05 · HIV Infections, Depression, Mild Cognitive Impairment
What this study did
NCT01101893 · ViiV Healthcare
2010-04 – 2010-06 · Infection, Human Immunodeficiency Virus
What this study did
NCT00660972 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-05 – 2010-04 · HIV Infections
What this study did
NCT01027182 · Changi General Hospital
2009-12 – 2010-03 · Human Immunodeficiency Virus
What this study did
NCT01047995 · St Stephens Aids Trust
2009-06 – 2009-12 · HIV Infections
What this study did
NCT00944307 · University of Colorado, Denver
2009-07 – 2009-12 · HIV Infections
What this study did
NCT00982553 · Imperial College London
2009-09 – 2009-12 · HIV Infections
What this study did
NCT01000818 · Merck Sharp & Dohme LLC
2008-06 – 2009-03 · HIV-1 Infection, HIV Infections
What this study did
NCT00765271 · St Stephens Aids Trust
2008-05 – 2008-10 · HIV
What this study did
NCT00618241 · Radboud University Medical Center
2008-02 – 2008-10 · HIV Infection
What this study did
NCT00665717 · Radboud University Medical Center
2008-05 – 2008-10 · HIV Infections
What this study did
NCT00531999 · St Stephens Aids Trust
2007-10 – 2008-08 · HIV Infections
What this study did
NCT00772551 · St Stephens Aids Trust
2008-06 – 2008-08 · HIV
What this study did
NCT00518297 · Bristol-Myers Squibb
2007-08 – 2007-12 · HIV Infections
What this study did
Other / comorbidity
NCT02655471 · Universidad Peruana Cayetano Heredia
2017-07-01 – 2019-03-15 · HTLV-I Infections, Tropical Spastic Paraparesis
What this study did
NCT01867320 · National Institute of Neurological Disorders and Stroke (NINDS)
2013-09-05 – 2018-09-25 · HTLV-I Infection
What this study did
NCT03537404 · R-Pharm
2017-04-24 – 2017-06-30 · Healthy
What this study did
NCT01275183 · New Mexico Cancer Research Alliance
2010-12 – 2015-04 · Head and Neck Cancer
What this study did
NCT01330199 · University of North Carolina, Chapel Hill
2012-02 – 2013-08 · Healthy Adult Females
What this study did
NCT01785160 · Boehringer Ingelheim
2013-02 – 2013-03 · Healthy
What this study did
NCT01531647 · Hoffmann-La Roche
2012-01 – 2012-03 · Healthy Volunteer
What this study did
NCT01325051 · Angela Kashuba, PharmD
2011-04 – 2011-11 · Healthy Volunteer
What this study did
NCT00809718 · The University of Texas Health Science Center at San Antonio
2009-02 – 2011-08 · Healthy
What this study did
NCT01253551 · Tibotec BVBA
2010-12 – 2011-04 · Hepatitis C
What this study did
NCT01241773 · Tibotec Pharmaceuticals, Ireland
2010-10 – 2011-04 · Hepatitis C Virus
What this study did
NCT00772720 · Hospital Clinic of Barcelona
2010-03 – 2011-03 · Healthy Volunteers
What this study did
NCT02182375 · Boehringer Ingelheim
2010-01 – 2010-03 · Healthy
What this study did
NCT00784420 · Pfizer
2008-09 – 2008-11 · Healthy Volunteers
What this study did
NCT00746499 · University of North Carolina, Chapel Hill
2008-09 – 2008-11 · Pharmacokinetics
What this study did
Phase 4 (65)
HIV
NCT04258475 · Ottawa Hospital Research Institute
2020-12-09 – 2025-01-01 · Calcium Supplementation in HIV Patients Using Raltegravir
What this study did
NCT02210715 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2015-03 – 2023-01-30 · HIV, Fatty Liver, Nonalcoholic Steatohepatitis
What this study did
NCT01147107 · University of Hawaii
2014-02 – 2021-06-01 · Hepatitis C, Chronic, HIV Infection
What this study did
NCT02691065 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2017-01-20 – 2021-03-31 · HIV
What this study did
NCT03842488 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2019-04 – 2021-03 · HIV Infections
What this study did
NCT03732625 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2019-05 – 2021-01 · HIV Infections
What this study did
NCT03374358 · Helsinki University Central Hospital
2018-01-10 – 2019-11-30 · HIV Seropositivity, Metabolic Syndrome, Fatty Liver
What this study did
NCT01641367 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2013-02-22 – 2018-12-31 · HIV-1 Infection
What this study did
NCT03667547 · Merck Sharp & Dohme LLC
2018-09-27 – 2018-10-23 · Human Immunodeficiency Virus (HIV) Infection
What this study did
NCT03205566 · Guy's and St Thomas' NHS Foundation Trust
2017-09-19 – 2018-09-24 · Hiv
What this study did
NCT02577042 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2015-10-15 – 2018-06-04 · Aging-related Inflammation in HIV-infected Patients
What this study did
NCT01989910 · Taipei Veterans General Hospital, Taiwan
2013-09 – 2017-12 · HIV-1 Infection
What this study did
NCT01829802 · Pedro Cahn
2014-05 – 2017-10 · Chronic Infection With HIV
What this study did
NCT02383355 · Radboud University Medical Center
2015-03-01 – 2017-07-01 · HIV
What this study did
NCT02351908 · St Stephens Aids Trust
2015-03 – 2017-04 · HIV
What this study did
NCT01900015 · Juan Macías
2014-02-03 – 2017-01-17 · HCV Coinfection, HIV Infection
What this study did
NCT01902186 · Giovanni Di Perri
2014-09 – 2016-12 · HIV Infection, Osteopenia
What this study did
NCT01214759 · The University of Texas Health Science Center, Houston
2011-05 – 2015-08 · HIV
What this study did
NCT01285050 · Johns Hopkins University
2011-01 – 2015-04 · HIV Infection, Hepatitis C
What this study did
NCT01679964 · Lin, Hsi-Hsun, M.D.
2012-07 – 2015-02 · HIV Infection, Adverse Drug Reaction, Quality of Life
What this study did
NCT01453933 · UMC Utrecht
2012-01 – 2014-12 · HIV Infection, Endothelial Dysfunction
What this study did
NCT01258439 · St Vincent's Hospital, Sydney
2010-11 – 2014-07 · HIV, Cardiovascular Disease
What this study did
NCT00939874 · St Vincent's Hospital, Sydney
2009-10 – 2014-04 · HIV, Osteopenia, Osteoporosis, HIV Infections
What this study did
NCT01332227 · Bristol-Myers Squibb
2011-10 – 2014-02 · HIV, Combination Therapy
What this study did
NCT00843713 · University of California, San Francisco
2009-01 – 2014-02 · HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
What this study did
NCT00781287 · University of Washington
2009-02 – 2013-10 · Human Immunodeficiency Virus
What this study did
NCT01448486 · St Vincent's Hospital, Sydney
2011-10 – 2013-10 · Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
What this study did
NCT01025427 · University of California, San Francisco
2009-12 – 2013-10 · HIV, HIV Infections
What this study did
NCT01513122 · Kirby Institute
2010-02 – 2013-08 · HIV
What this study did
NCT01245101 · University of Miami
2010-11 – 2013-05 · HIV
What this study did
NCT01059422 · Central Institute of Epidemiology, Moscow, Russia
2010-10 – 2013-05 · HIV Infections, Tuberculosis
What this study did
NCT01270802 · Indiana University
2011-04 – 2013-04 · HIV
What this study did
NCT00762892 · The University of Texas Health Science Center, Houston
2009-01 – 2013-01 · HIV Infections
What this study did
NCT01105611 · St. James's Hospital, Ireland
2010-08 – 2012-12 · HIV Infections, Hepatitis C
What this study did
NCT00677300 · Dallas VA Medical Center
2009-01 – 2012-12 · HIV Infections
What this study did
NCT01335620 · Imperial College London
2011-04 – 2012-12 · HIV
What this study did
NCT01173510 · Community Research Initiative of New England
2010-08-23 – 2012-10-19 · HIV Infections, Acquired Immune Deficiency Syndrome
What this study did
NCT01201239 · Shanghai Public Health Clinical Center
2010-09 – 2012-10 · HIV
What this study did
NCT01225705 · University Hospital, Bonn
2010-10 – 2012-08 · HIV, Hepatitis C
What this study did
NCT01087840 · Andrew Carr
2010-07 – 2012-07 · HIV Prevention, HIV Infections
What this study did
NCT00773708 · Germans Trias i Pujol Hospital
2009-03 – 2011-05 · HIV Infections
What this study did
NCT01121809 · Hospitales Universitarios Virgen del Rocío
2010-04 – 2011-01 · HIV-1 Infection, HIV Infections
What this study did
Early phase / not applicable (31)
HIV
NCT01978743 · Massachusetts General Hospital
2014-01 – 2017-01 · HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity
What this study did
NCT02611895 · University Hospital, Montpellier
2015-03 – 2016-12-31 · HIV-1 Infection
What this study did
NCT01844310 · Peking Union Medical College
2013-05 – 2015-12 · AIDS/HIV PROBLEM
What this study did
NCT01450189 · University of North Carolina, Chapel Hill
2011-10 – 2014-07 · HIV
What this study did
NCT01204905 · University of Maryland, Baltimore
2010-09 – 2014-05-16 · HIV Infections
What this study did
NCT00525733 · Rockefeller University
2007-10 – 2013-12 · HIV Infections
What this study did
NCT01294761 · National Center for Global Health and Medicine, Japan
2011-02 – 2013-12 · HIV Infections
What this study did
NCT01293123 · University of California, San Diego
2011-12 – 2013-12 · HIV
What this study did
NCT00814879 · Yale University
2009-05 – 2013-11 · Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT01318096 · Yunnan AIDS Care Center
2011-03 – 2013-09 · HBV Coinfection, HIV Infections
What this study did
NCT01164605 · Southern California Institute for Research and Education
2010-10 – 2013-06 · HIV Infection
What this study did
NCT01327482 · University of Washington
2011-10 – 2012-12 · HIV
What this study did
NCT00734344 · University of Alabama at Birmingham
2008-09 – 2012-09 · Acute HIV Infection
What this study did
NCT01042652 · Centers for Disease Control and Prevention, China
2011-02 – 2012-06 · HIV, HIV Infections
What this study did
NCT00749580 · University of South Florida
2008-11 – 2011-07 · Virus Diseases, HIV
What this study did
NCT00661960 · University of California, Davis
2008-03 – 2011-07 · HIV Infections, AIDS
What this study did
NCT01214486 · University of Nebraska
2010-10-01 – 2011-06-30 · HIV
What this study did
NCT00745368 · University of Rochester
2008-09 – 2011-06 · HIV Infections
What this study did
NCT01044771 · Metropolis Medical
2010-01 – 2011-06 · HIV Infections, Proteinuria
What this study did
NCT00641641 · Kirby Institute
2008-03 – 2011-06 · HIV Infection
What this study did
NCT00863668 · University of Minnesota
2009-03 – 2011-03 · HIV Infection, HIV Infections
What this study did
NCT00672932 · University of California, San Francisco
2008-04 – 2011-02 · HIV Infections
What this study did
NCT00738569 · National Jewish Health
2008-07 – 2011-02 · HIV
What this study did
NCT00523237 · Stanford University
2007-10 – 2010-12 · HIV Infections
What this study did
NCT00884793 · University of California, San Francisco
2008-09 – 2010-12 · HIV Infections
What this study did
NCT00944957 · University Hospital, Geneva
2009-11 – 2010-04 · Sleep Disorders, HIV Infections
What this study did
NCT00787774 · Hospital Clinic of Barcelona
2008-11 – 2010-01 · HIV Infection
What this study did
NCT00858962 · Yale University
2009-03 – 2009-12 · HIV Infection, HIV Infections
What this study did
NCT00618371 · University of Pittsburgh
2007-10 – 2009-03 · HIV Infection
What this study did
Other / comorbidity
NCT00802074 · Garden State Infectious Disease Associates, PA
2008-12 – 2009-04 · Healthy
What this study did
NCT00614991 · Garden State Infectious Disease Associates, PA
2008-01 – 2008-03 · Healthy
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (5)
HIV
NCT01231516 · ViiV Healthcare
2010-10-26 – 2021-02-02 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT02273765 · ANRS, Emerging Infectious Diseases
2015-09-11 – 2018-11-28 · HIV-1 Infection, Tuberculosis
What this study did
NCT02219672 · Peking Union Medical College
2014-07 – 2017-07 · AIDS/HIV PROBLEM
What this study did
NCT01227824 · ViiV Healthcare
2010-10-19 – 2016-12-27 · Infection, Human Immunodeficiency Virus I
What this study did
NCT00708162 · Gilead Sciences
2008-07 – 2015-04 · HIV Infection
What this study did
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
HIV
NCT01896921 · University of Maryland, Baltimore
2013-09 – 2018-12 · HIV
What this study did
NCT01033760 · ANRS, Emerging Infectious Diseases
2010-04 – 2013-12 · HIV-1 Infections
What this study did
Phase 2/3 (1)
HIV
NCT02150993 · ANRS, Emerging Infectious Diseases
2016-01-26 – 2019-05-15 · HIV-2 Infection
What this study did
Early phase / not applicable (1)
HIV
NCT03394196 · University of Washington
2018-07-04 – 2020-05-31 · HIV-2 Infection
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for HIV: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Raltegravir (Isentress): this drugApprovedSmall moleculeHIV integraseReliable signal
NCT00293254: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3)
NCT00293267: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.7% (95% CI 71.8 to 82.9) vs Placebo + OBT 41% (95% CI 32 to 50.5)
Amprenavir
ApprovedUS marketing discontinued
Small moleculeHIV proteasenot yet gradedNo reviewed efficacy summary in this indication
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integraseReliable signal
NCT03110380: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis).
NCT02607956: Week 48 HIV-1 RNA <50 copies/mL: 89.4% B/F/TAF vs 92.9% DTG + F/TAF; difference -3.5 percentage points (95.002% CI -7.9 to 1.0); prespecified non-inferiority margin 12%.
Bictegravir / Lenacapavir (Bixlenvo)ApprovedSmall moleculeHIV integrase, HIV capsidPartial signal
NCT05502341: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results).
Cabotegravir (Apretude)ApprovedSmall moleculeHIV integraseReliable signal
NCT02720094: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281
Cabotegravir / Rilpivirine (Cabenuva)ApprovedSmall moleculeHIV integrase, HIV reverse transcriptaseWeak signal
NCT03299049: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results).
NCT02938520: Virologic failure (HIV-1 RNA >=50 copies/mL, FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 4 weeks vs abacavir/dolutegravir/lamivudine: 2.1% vs 2.5%, adjusted difference -0.4% (95% CI -2.8 to 2.1); non-inferior against the 6% margin (CT.gov posted results).
Darunavir (Prezista)ApprovedSmall moleculeHIV proteasePartial signal
NCT00110877: HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16).
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component))ApprovedSmall moleculeHIV integraseReliable signal
NCT01263015: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003).
NCT01449929: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 (Week 48): DTG 50 mg QD 90% vs DRV 800 mg + RTV 100 mg QD 83%
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02403674: Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033).
NCT02275780: Week 48 HIV-1 RNA <50 copies/mL: 83.8% doravirine vs 79.9% darunavir/ritonavir; treatment difference 3.913 percentage points (95% CI -1.590 to 9.415), non-inferiority margin -10 percentage points.
Doravirine / Islatravir (Idvynso)ApprovedSmall moleculeHIV reverse transcriptase, HIV-1 Reverse TranscriptasePartial signal
NCT05630755: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results).
NCT04233879: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3%
Elvitegravir (Stribild)ApprovedSmall moleculeHIV integrasePartial signal
NCT01095796: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1%
Emtricitabine (Emtriva)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00112047: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00323544: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm.
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00254046: Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005
NCT00255099: Confirmed viral load <50 copies/mL at Week 24 (intention to treat): etravirine (TMC125) 62% (183/295) vs placebo 44% (129/296); difference 18% (95% CI 11-26; p=0.0003).
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120Partial signal
NCT02362503: Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007)
NCT01384734: HIV-1 RNA < 50 copies/mL at Week 24: fostemsavir 400 mg BID 80% (95% CI 66.3 to 90), 800 mg BID 69% (54.6 to 81.7), 600 mg QD 76% (62.5 to 87.2) and 1200 mg QD 72% (57.5 to 83.8) vs the atazanavir/ritonavir reference arm 75% (60.4 to 85.7).
Ibalizumab (Trogarzo)ApprovedMonoclonal antibodyCD4 receptorWeak signal
NCT02475629: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%)
Lenacapavir (Sunlenca)ApprovedSmall moleculeHIV capsidPartial signal
NCT04150068: Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants
NCT04143594: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 54): Group 1: SC LEN+(F/TAF→ TAF) 90.4% vs Group 2: SC LEN + (F/TAF → BIC) 84.9% vs Group 3: Oral LEN + F/TAF 84.6% vs Group 4: B/F/TAF 92.0%; p=0.7178 (Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF), p=0.3900 (Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF), p=0.3797 (Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF) missed
Lenacapavir (Yeztugo)ApprovedSmall moleculeHIV capsidReliable signal
NCT04925752: HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025).
NCT04994509: HIV incidence: 0 infections in 2,134 on twice-yearly lenacapavir (0 per 100 PY; 95% CI 0.00-0.19) vs background incidence 2.41 per 100 PY (IRR 0.00; 95% CI 0.00-0.04; P<0.001) and vs F/TDF 1.69 per 100 PY (IRR 0.00; 95% CI 0.00-0.10; P<0.001) (PURPOSE 1, NEJM 2024).
Maraviroc (Selzentry / Celsentri)ApprovedSmall moleculeCCR5 co-receptorPartial signal
NCT00098293: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3%
Rilpivirine (Edurant)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00540449: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%.
NCT00543725: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 (Week 48): TMC278 — Responder: 291/340; Virologic failure: 24/340; Death: 1/340; Discontinued due to AE: 8/340; Discontinued due to other reason than AE: 16/340 vs Efavirenz — Responder: 276/338; Virologic failure: 18/338; Death: 3/338; Discontinued due to AE: 21/338; Discontinued due to other reason than AE: 20/338
Somatropin (Serostim)ApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signal
NCT00082628: Change in visceral adipose tissue area at Week 12: -32.6 cm² Serostim (n=210) vs 0.5 cm² placebo (n=74), p<0.001. phase 3 result · pivotal pending
NCT01077960: Primary endpoint: mean change in trunk fat from baseline to week 12, -1.7 kg (SD 1.4; n=106; p<0.001). phase 3 result · pivotal pending
Tenofovir Alafenamide / Emtricitabine (Descovy)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02842086: Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564)
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Partial signal
NCT00528957: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 (48 weeks): Tenofovir DF 83.3 percentage of participants | Stavudine or Zidovudine 91.8 percentage of participants | All TDF 85.4 percentage of participants missed
NCT00352053: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA (Baseline to 24 Weeks): Tenofovir DF -1.58 log10 copies/mL (IQR -2.15 to -0.27) | Placebo -1.549 log10 copies/mL (IQR -2.36 to -0.34) missed
Tesamorelin (Egrifta WR)ApprovedPeptideGrowth hormone-releasing hormone (GHRH) receptorPartial signal
NCT00608023: Changes From Baseline in Fasting Blood Glucose at Week 52 (Baseline and Week 52): Tesamorelin 52 Weeks 0 mg/dL (Standard Deviation 16) missed
Tipranavir (Aptivus)ApprovedSmall moleculeHIV proteasePartial signal
NCT00144170: Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15%
NCT00054717: Treatment Response at Week 48 (At week 48): Tipranavir(TPV)/Low Dose Ritonavir(r) 33.8% vs Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r) 16.2%
ACC017Phase 3Small moleculeHIV integrasePartial signal
NCT06719310: The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29.
Albuvirtide (Aikening)Phase 3PeptideHIV gp41Partial signal
NCT02369965: Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met.
AlimatravirPhase 3Small moleculeHIV-1 Reverse TranscriptaseWeak signal
NCT06045507: Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results).
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasePartial signal
NCT04109183: 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05)
Dapivirine (Dapivirine Vaginal Ring)Phase 3Small moleculeHIV reverse transcriptaseReliable signal
NCT01617096: HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007).
IslatravirPhase 3Small moleculeHIV-1 Reverse Transcriptasenot yet gradedNo reviewed efficacy summary in this indication
Islatravir / LenacapavirPhase 3Small moleculeHIV-1 Reverse Transcriptase, HIV capsidnot yet gradedNo reviewed efficacy summary in this indication
SemzuvolimabPhase 3Monoclonal antibodyCD4 receptorWeak signalNo reviewed efficacy summary in this indication
TeropavimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
ZinlirvimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
Elsulfavirine (Elpida)Phase 2/3Small moleculeHIV reverse transcriptasePartial signalNo reviewed efficacy summary in this indication
LeronlimabPhase 2/3Monoclonal antibodyCCR5 co-receptorWeak signal
NCT02483078: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77%
NCT02859961: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure (From T1 (first treatment administration) to week 48 (T48).): Part 1 - 350 mg Weekly Injections of PRO 140, Group A 23% | Part 1 - 525 mg Weekly Injections of PRO 140, Group B 43% | Part 1 - 700 mg Weekly Injections of PRO 140, Group C 45%
UlonivirinePhase 2/3Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
10-1074Phase 2Monoclonal antibodyHIV envelopeWeak signalFeatured results are safety only in this race
3BNC117Phase 2Monoclonal antibodyHIV envelopePartial signal
NCT03041012: Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed.
CL-197Phase 2Small moleculeHIV reverse transcriptaseWeak signalNo reviewed efficacy summary in this indication
DezecapavirPhase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969)
EnvafolimabPhase 2Monoclonal antibodyPD-L1Weak signalNo reviewed efficacy summary in this indication
HTI Vaccine (ChAdOx1.HTI / MVA.HTI)Phase 2VaccineHIV-1 conserved epitopes (HTI)Partial signal
NCT03204617: Primary, safety (grade 3 or 4 local and systemic reactions; no formal efficacy test): adverse events were mostly mild and transient, with no related serious adverse events. Secondary: HTI vaccines induced strong, broad CD4 and CD8 T-cell responses; all participants had detectable viral rebound during treatment interruption.
LipovirtidePhase 2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
LotivibartPhase 2Monoclonal antibodyHIV envelopeWeak signal
NCT04871113: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69)
TMB-365 / TMB-380Phase 2CombinationCD4; HIV envelopenot yet gradedNo reviewed efficacy summary in this indication
TrosunilimabPhase 2Monoclonal antibodyα4β7 integrinPartial signalFeatured results are safety only in this race
VesatolimodPhase 2Small moleculeToll-like receptor 7 (TLR7) (agonist)Weak signalFeatured results are safety only in this race
VH4004280 (VH-280)Phase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574)
VH4524184Phase 2Small moleculeHIV integrasePartial signal
NCT06214052: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37)
JL18008Phase 1/2Protein / enzyme therapeuticIL-7 receptorWeak signalNo reviewed efficacy summary in this indication
LP-98Phase 1/2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
AGT103-TPhase 1Gene therapy / editingHIV proviral reservoir / autologous T cellsWeak signalFeatured results are safety only in this race
AinuovirinePhase 1Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
AV000103A (ICVAX)Phase 1VaccineHIV antigensWeak signalFeatured results are safety only in this race
BNT168Phase 1VaccineHIV antigensnot yet gradedNo reviewed efficacy summary in this indication
BNT351Phase 1Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
CPT31Phase 1PeptideHIV gp41Weak signalFeatured results are safety only in this race
MGD014Phase 1Multispecific antibodyHIV envelope gp120 x CD3Weak signalFeatured results are safety only in this race
MGD020Phase 1Multispecific antibodyHIV envelope gp41 x CD3Weak signalFeatured results are safety only in this race
MK-4646Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
UVAX-1107Phase 1VaccineHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
VH4770359Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Islatravir / Ulonivirine
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
YASO GEL
—(overall)
Small moleculeHIV gp120not yet gradedNo reviewed efficacy summary in this indication
Fosamprenavir (Lexiva / Telzir)DiscontinuedSmall moleculeHIV proteasePartial signal
NCT00450580: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks (Week 48): FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q — HIV-1 RNA <400 copies/mL: 81%; HIV-1 RNA >=400 copies/mL: 19% | FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD — HIV-1 RNA <400 copies/mL: 82%; HIV-1 RNA >=400 copies/mL: 18%
NCT00363142: Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 (Week 24): FPV/r100 92.1% | FPV/r200 94.2%
VH4527079DiscontinuedMultispecific antibodyHIV entrynot yet gradedNo reviewed efficacy summary in this indication
ZegruvirimatDiscontinuedSmall moleculeHIV-1 Gag maturation (CA-SP1 cleavage)Partial signal
NCT06061081: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA). (From Day 1 to Day 8): VH3739937 Low Dose Group -116909.43 copies/milliliter (c/mL) (Standard Deviation 187489.611) | VH3739937 Medium Dose Group -130461.67 copies/milliliter (c/mL) (Standard Deviation 106486.489) | VH3739937 High Dose Group -126026.67 copies/milliliter (c/mL) (Standard Deviation 190725.475) vs Placebo Once Daily (QD) -428000 copies/milliliter (c/mL) | Placebo Single Dose (SD) -14200 copies/milliliter (c/mL)

Compare side by side

2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Isentress (Raltegravir) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
Phase 1/2HIVRecruiting
Est. primary completion 2028-01-31 · NCT02140255 · CT.gov ↗
What to watch

See the full readout calendar ↗